These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 33904521)

  • 41. Eplerenone for hypertension.
    Tam TS; Wu MH; Masson SC; Tsang MP; Stabler SN; Kinkade A; Tung A; Tejani AM
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008996. PubMed ID: 28245343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of a selective aldosterone blocker and thiazide-type diuretic on blood pressure and organ damage in hypertensive patients.
    Ohta Y; Ishizuka A; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2015; 37(7):569-73. PubMed ID: 25992488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.
    Ritter AM; Fontana V; Faria AP; Modolo R; Barbaro NR; Sabbatini AR; Peres H; Biagi C; Silva PS; Lopes PC; Tanus-Santos JE; Coelho EB; Moreno H
    Am J Hypertens; 2016 Feb; 29(2):245-50. PubMed ID: 26049084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV.
    Srinivasa S; Fitch KV; Wong K; O'Malley TK; Maehler P; Branch KL; Looby SE; Burdo TH; Martinez-Salazar EL; Torriani M; Lyons SH; Weiss J; Feldpausch M; Stanley TL; Adler GK; Grinspoon SK
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2376-2384. PubMed ID: 29659888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels.
    van Leeuwen N; Caprio M; Blaya C; Fumeron F; Sartorato P; Ronconi V; Giacchetti G; Mantero F; Fernandes-Rosa FL; Simian C; Peyrard S; Zitman FG; Penninx BW; de Kloet ER; Azizi M; Jeunemaitre X; Derijk RH; Zennaro MC
    Hypertension; 2010 Nov; 56(5):995-1002. PubMed ID: 20855654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
    Baudrand R; Gupta N; Garza AE; Vaidya A; Leopold JA; Hopkins PN; Jeunemaitre X; Ferri C; Romero JR; Williams J; Loscalzo J; Adler GK; Williams GH; Pojoga LH
    J Am Heart Assoc; 2016 Sep; 5(10):. PubMed ID: 27680666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.
    Brandt-Jacobsen NH; Johansen ML; Rasmussen J; Forman JL; Holm MR; Faber J; Rossignol P; Schou M; Kistorp C
    Diabetes Metab; 2021 Jul; 47(4):101190. PubMed ID: 32919068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
    Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
    Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
    Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
    Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus.
    Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Yamagishi M; Takeda Y
    Clin Exp Hypertens; 2016; 38(7):565-570. PubMed ID: 27651039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aldosterone and aldosterone antagonism in systemic hypertension.
    Frishman WH; Stier CT
    Curr Hypertens Rep; 2004 Jun; 6(3):195-200. PubMed ID: 15128471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Barrios V; Brommer P; Haag U; Calderón A; Escobar C
    Clin Drug Investig; 2009; 29(7):427-439. PubMed ID: 19499960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.
    Kalizki T; Schmidt BMW; Raff U; Reinold A; Schwarz TK; Schneider MP; Schmieder RE; Schneider A
    J Clin Hypertens (Greenwich); 2017 Jul; 19(7):669-676. PubMed ID: 28211216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.